| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS30079525 | HIV | ENSG00000165731.22 | protein_coding | RET | Yes | No | 5979 | P07949 |
| TVIS30027580 | HIV | ENSG00000165731.22 | protein_coding | RET | Yes | No | 5979 | P07949 |
| TVIS20046217 | HPV | ENSG00000165731.22 | protein_coding | RET | Yes | No | 5979 | P07949 |
| TVIS44026438 | HTLV-1 | ENSG00000165731.22 | protein_coding | RET | Yes | No | 5979 | P07949 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | RET |
|---|---|
| DrugBank ID | DB08901 |
| Drug Name | Ponatinib |
| Target ID | BE0002411 |
| UniProt ID | P07949 |
| Regulation Type | inhibitor |
| PubMed IDs | 23526464 |
| Citations | De Falco V, Buonocore P, Muthu M, Torregrossa L, Basolo F, Billaud M, Gozgit JM, Carlomagno F, Santoro M: Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer. J Clin Endocrinol Metab. 2013 May;98(5):E811-9. doi: 10.1210/jc.2012-2672. Epub 2013 Mar 22. |
| Groups | Approved; Investigational |
| Direct Classification | Benzanilides |
| SMILES | CN1CCN(CC2=CC=C(NC(=O)C3=CC(C#CC4=CN=C5C=CC=NN45)=C(C)C=C3)C=C2C(F)(F)F)CC1 |
| Pathways | Ponatinib Inhibition of BCR-ABL |
| PharmGKB | PA165980594 |
| ChEMBL | CHEMBL1171837 |
